This Article Full Text (PDF) Other Versions of this Article: CVI.00169-08v1 15/9/1429    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by del Rio, B. Articles by Gomes-Solecki, M. PubMed PubMed Citation Articles by del Rio, B. Articles by Gomes-Solecki, M.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00169-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Oral immunization with recombinant Lactobacillus plantarum induces a protective immune response in the Lyme disease mouse model

Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA; Biopeptides Corp., Valhalla, NY, USA; Falco Biotherapeutics BV (previously Lactrys Biopharmaceuticals BV), Zernikedreef 9, 2331 CK Leiden, The Netherlands

^* To whom correspondence should be addressed. Email: mgomesso{at}utmem.edu.

	Abstract

Mucosal immunization is advantageous over other routes of antigen delivery because it can induce both mucosal and systemic immune responses. Our goal was to develop a mucosal delivery vehicle based on bacteria "generally regarded as safe", such as Lactobacillus spp. In this study, we used the Lyme disease mouse model as a proof of concept. We demonstrate that an oral vaccine based in live recombinant Lactobacillus plantarum protects mice from tick transmitted Borrelia burgdorferi infection. Our method of expressing vaccine antigens in L. plantarum induces both systemic and mucosal immunity after oral administration. This platform technology can be applied to design oral vaccine delivery vehicles against several microbial pathogens.